Tenax Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 9 →Insiders4 insiders bought $189,556 in 13 open-market buys. No sales.→HoldersFMR 12.3%Vivo Capital 7.8%BlackRock 5.4%→Financing →PeersClosest companies: ELDN, VTVT, DWTX→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$64.9Mlast 12 months
- Operating cash flow
- −$38.1Mlast 12 months
- Cash and equivalents
- $118.0Mat the last balance sheet
- Shares outstanding
- 31.9M shareson issue